Nilotinib modulates LPS-induced cognitive impairment and neuroinflammatory responses by regulating P38/STAT3 signaling

BACKGROUND: In chronic myelogenous leukemia, reciprocal translocation between chromosome 9 and chromosome 22 generates a chimeric protein, Bcr-Abl, that leads to hyperactivity of tyrosine kinase-linked signaling transduction. The therapeutic agent nilotinib inhibits Bcr-Abl/DDR1 and can cross the bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jieun, Lee, Hyun-ju, Park, Jin-Hee, Cha, Byung-Yoon, Hoe, Hyang-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288088/
https://www.ncbi.nlm.nih.gov/pubmed/35841100
http://dx.doi.org/10.1186/s12974-022-02549-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288088/
https://www.ncbi.nlm.nih.gov/pubmed/35841100
http://dx.doi.org/10.1186/s12974-022-02549-0

Ejemplares similares